Cella D, et al. - Researchers compared the health-related quality of life (HRQoL) of advanced renal cell carcinoma patients who were randomly assigned (1:1) to open-label nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for four doses followed by nivolumab 3 mg/kg every 2 weeks, or sunitinib 50 mg/day for 4 weeks of each 6-week cycle in the ongoing phase 3, CheckMate 214 trial. Nivolumab plus ipilimumab has already been shown to improve overall survival compared with sunitinib in patients (aged 18 years and older) with intermediate or poor risk, previously untreated, advanced renal cell carcinoma. Compared with sunitinib, nivolumab plus ipilimumab offered more favorable patient-reported outcomes throughout the first 103 weeks after baseline. Overall, fewer symptoms and better HRQoL were observed in patients treated with nivolumab plus ipilimumab vs sunitinib, suggesting the additional benefit of improved HRQoL with nivolumab plus ipilimumab along with its superiority over sunitinib.